Our round-up of notable biotech financings in the last week includes a $120 million direct offering for immunology and inflammation biotech iTeos, and private rounds for Lycia, Attovia, Ajax, and ...
B2B is often seen to lag behind B2C in marketing, and nowhere is that more true than in the pharmaceuticals industry. Pharma isn’t exactly known for its creativity, and brand-building often ...
In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...
Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...
GSK plans U.S. launch in second half of the year GSK expects Blujepa and other drugs to contribute to over £2 billion in peak sales Blujepa's unique action reduces bacterial resistance risk, GSK ...
For much of her early career, Shobie Ramakrishnan called Silicon Valley home. GSK’s chief digital and technology officer ...
LONDON, March 25 (Reuters) - GSK (GSK.L), opens new tab said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its best-selling shingles ...
The Food and Drug Administration on Tuesday approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new approvals the British drugmaker ...
GSK Plc is pushing the UK government to give pharmaceutical companies more access to its public health data troves, to accelerate drug development and halt the nation’s slide down global life ...
GSK plc (NYSE:GSK) is engaged in research, development, and production of vaccines, as well as specialized and general medicines aimed at preventing and treating various diseases. In early March, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback